Free Trial

8 Retail Stocks to Own For the Long Haul - 8 of 8

 
 

O'Reilly Automotive (NASDAQ:ORLY)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
13 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$1,144.06 (0.2% Downside)

About O'Reilly Automotive

OO'Reilly Automotive, Inc, together with its subsidiaries, operates as a retailer and supplier of automotive aftermarket parts, tools, supplies, equipment, and accessories in the United States, Puerto Rico, and Mexico. The company provides new and remanufactured automotive hard parts and maintenance items, such as alternators, batteries, brake system components, belts, chassis parts, driveline parts, engine parts, fuel pumps, hoses, starters, temperature control, water pumps, antifreeze, appearance products, engine additives, filters, fluids, lighting products, and oil and wiper blades; and accessories, including floor mats, seat covers, and truck accessories. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
8/22/2024Wells Fargo & CompanyBoost Price TargetOverweight ➝ Overweight$1,200.00 ➝ $1,250.00
8/22/2024Evercore ISIBoost Price TargetOutperform ➝ Outperform$1,215.00 ➝ $1,230.00
8/22/2024Bank of AmericaBoost Price TargetBuy ➝ Buy$1,204.00 ➝ $1,290.00
7/26/2024DA DavidsonBoost Price TargetBuy ➝ Buy$1,200.00 ➝ $1,275.00
7/26/2024Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$1,124.00 ➝ $1,115.00
7/26/2024Truist FinancialBoost Price TargetBuy ➝ Buy$1,143.00 ➝ $1,204.00
7/25/2024WedbushReiterated RatingNeutral ➝ Neutral$1,100.00 ➝ $1,100.00
7/18/2024UBS GroupLower Price TargetBuy ➝ Buy$1,275.00 ➝ $1,250.00
7/16/2024Evercore ISILower Price TargetOutperform ➝ Outperform$1,250.00 ➝ $1,225.00
7/2/2024Evercore ISILower Price TargetOutperform ➝ Outperform$1,275.00 ➝ $1,250.00

More Investing Slideshows:

 

FDA’s hidden signal greenlights biotech winners — 97% of the time (Ad)

The FDA has started to quietly send out a signal … That has given investors a 97% chance of making money. Perhaps as soon as 9:30 a.m. tomorrow.

Click here to find out how you can get in before the FDA’s potential signal.